Neurizon Therapeutics Limited
Share Statistics
As of June 30, 2025, NEURIZON THERAPEUTICS LTD. has 496.02M shares outstanding.
| Shares Outstanding | 496.02M |
Financial Position
As of June 30, 2025, NEURIZON THERAPEUTICS LTD. maintains a current ratio of 2.84, meaning it holds 2.8x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 2.84 |
| Quick Ratio | 2.73 |
Financial Efficiency
Over the twelve months ended June 30, 2025, NEURIZON THERAPEUTICS LTD. posted a negative return on equity (ROE) of -254.33, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -214.34, reflecting losses generated across the asset base.
| Return on Equity (ROE) | -254.33 |
| Return on Assets (ROA) | -214.34 |
Income Statement
USDThese figures cover the twelve months ended June 30, 2025. EBITDA reached -12.16M, while operating income came in at -12.16M.
| Operating Income | -12.16M |
| Pretax Income | -10.92M |
| Net Income | -10.92M |
| EBITDA | -12.16M |
| EBIT | -12.16M |
| Earnings Per Share (EPS) | -0.02 |
Balance Sheet
USDThese figures are as of June 30, 2025. Total book value stands at 1.86M, with working capital of 1.86M providing operational flexibility.
| Cash & Cash Equivalents | 2.75M |
| Net Debt | -2.74M |
| Equity (Book Value) | 1.86M |
| Working Capital | 1.86M |
Cash Flow
USDThese figures cover the twelve months ended June 30, 2025.
| Capital Expenditures | -1,016.85 |
Stock Splits
NEURIZON THERAPEUTICS LTD.'s most recent stock split took place on December 29, 2025.
| Last Split Date | 12/29/2025 |